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Abstract
Background: Children with Prader-Willi Syndrome (PWS) have been considered at risk for central adrenal
insufficiency (CAI). Hypothalamic dysregulation has been proposed as a common mechanism underlying both
stress-induced CAI and central respiratory dysfunction during sleep.
Objective: To evaluate CAI and sleep-related breathing disorders in PWS children.
Patients and methods: Retrospective study of cortisol response following either insulin tolerance test (ITT) or
glucagon test (GT) in 20 PWS children, and comparison with 33 non- Growth Hormone deficient (GHD) controls.
Correlation between sleep related breathing disorders and cortisol response in 11 PWS children who received both
investigations.
Results: In PWS children, the cortisol peak value showed a significant, inverse correlation with age (Kendall’s
τ = -0.411; p = 0.012). A similar though non-significant correlation was present between cortisol increase and age
(τ = -0.232; p = 0.16). Similar correlations were found in controls. In only 1 of 20 PWS children (5 %), ITT was
suggestive of CAI. Four patients had an elevated central apnea index but they all exhibited a normal cortisol
response. No relationship was found between peak cortisol or cortisol increase and central apnea index
(respectively p = 0.94 and p = 0.14) or the other studied polysomnography (PSG) parameters.
Conclusions: CAI assessed by ITT/GT is rare in PWS children. Our data do not support a link between CAI and
central respiratory dysregulation.
Keywords: Prader-Willi, Adrenal insufficiency, Sleep disorders
Background
The Prader-Willi Syndrome (PWS) is a rare, complex
neurogenic disorder caused by the loss of expression of
the paternally expressed genes from the 15q11-q13 region
[1]. The clinical symptoms are age-related: fetuses show a
marked decline of movements in utero, position abnor-
malities or polyhydramnios. Shortly after birth and during
the first year of life severe hypotonia, lethargy, breathing
difficulties and failure to thrive are prominent. During
infancy, growth deceleration and developmental delay
become evident, together with extreme hyperphagia and a
low metabolic rate, causing important obesity. Standard
treatment is controlled diet, regular physical exercise and
human recombinant growth hormone (GH), which nor-
malizes growth and improves exercise capacity, physical
strength, body composition and fat regulation [2, 3].
A dysfunctional hypothalamic-pituitary axis is assumed
to underlie several clinical features such as hyperphagia,
hypogonadism, aberrant energy regulation, inefficient GH
secretion and abnormal temperature regulation. Likewise,
hypothalamic dysfunction is thought to be responsible for
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the disturbed hypoxic ventilatory response commonly
seen in these patients. This, in combination with obesity,
respiratory muscle weakness, craniofacial abnormalities
and adenotonsillar hypertrophy, is thought to lead to the
well-known sleep-related breathing disorders (SRBD) in
PWS, including central (CA) and obstructive (OA) apneas,
and hypopneas. Whereas OA are strongly related to BMI,
and are mostly seen in older, obese PWS patients, CA
more commonly occur in non-obese, prepubertal PWS
children and have not been related to body weight or
BMI. In combination with the impaired or, in some cases,
even absent response towards hypoxia and hypercapnia,
CA are thought to result from a central dysfunctional
respiratory control, already present at an early age [4–8].
In addition, young PWS patients have an increased risk
of sudden death, especially during sleep. In a series of 64
PWS patients up to nineteen years of age, the main cause
of death (61 %) was a respiratory disorder - an upper re-
spiratory tract infection in the majority (44 %) of cases, and
suffocation or sudden death during sleep in the remaining
group (17 %), independent of GH treatment. The median
age at death was 3 years [9]. The cause of sudden death in
PWS is not known. de Lind van Wijngaarden et al. [10]
suggested that an unexpected and unexplainable death dur-
ing sleep in children with PWS could be caused by a stress-
induced central adrenal insufficiency (CAI), resulting from
a dysfunction of the hypothalamic-pituitary-hormonal axis.
This could explain the typical lack of symptoms during ill-
ness, the higher pain threshold and the low adrenal weight
reported during biopsy in patients with PWS. In this study,
an inadequate ACTH response to overnight single-dose
metyrapone was noticed in 60 % of 25 children with PWS.
At baseline, the CA index was higher in those PWS chil-
dren with CAI compared to those without. After adminis-
tration of metyrapone, the CA index increased more in
children with CAI as compared to children with normal
adrenal function, suggesting a link between CAI and sleep-
related breathing disorders (SRBD) probably due to a com-
mon hypothalamic dysfunction [11]. Other studies, based
on low-dose (LDST) and high-dose (HDST) ACTH tests
and insulin tolerance tests (ITT), did not confirm these data
and described a lower prevalence of CAI in PWS children
and adults, ranging between 0 to 14 % [12–15].
In order to gain further insight in the possible rela-
tionship between CAI and SRBD in children with PWS,
we decided to retrospectively analyze the presence of
CAI, based on ITT and GT performed within the
context of a global assessment at start of GH therapy in
Belgian children with PWS. Subsequent analysis of
polysomnographies (PSG) performed in a subset of
these children allowed evaluation of SRBD and pro-
vided argumentation concerning an eventual underlying
central hypothalamic dysfunction, responsible for both
CAI and SRBD.
Methods
Results of ITT and/or GT obtained in 20 PWS (genetically
confirmed) children, followed in the period 1997-2012 at
different tertiary care centers in Belgium, were retrospect-
ively reviewed. ITT and/or GT were performed before the
start of GH treatment in 15 patients. Five PWS patients
underwent an ITT and/or GT after the start of GH ther-
apy, but with a one week GH-free wash-out period. ITT
and GT had been performed according to previously
described protocols [16]. For comparison, results of ITT
or GT, obtained in 33 non-GHD otherwise healthy chil-
dren who were evaluated for short stature in the past
three years at the Ghent University Hospital and the Clini-
ques Universitaires Saint-Luc, were included as controls.
BMI was calculated as kg/m2 and expressed as z-score,
adjusted for age and sex, using the Cole BMI reference
data [17]. GH deficiency (GHD) was diagnosed on the
basis of local cut-off values for ITT and GT, and varied
according to the used assay at the time of testing.
Serum cortisol levels were determined using local routine
laboratory assays and were retrieved retrospectively. A cor-
tisol level exceeding 19.94 μg/dL (550 nM) and/or an
increase (calculated between the lowest cortisol and the
highest cortisol level during the stimulation test) greater
than 9.0 μg/dL (250 nM) were considered as a sufficient
cortisol response for both ITT and GT [18]. No direct
ACTH measurement was performed; the definition of CAI
was based on the interpretation of cortisol responses during
ITT or GT which are considered the golden standard for
the diagnosis of CAI [19, 20].
Subjects participated in one overnight video-
polysomnographic study. Basic recordings of the polysom-
nography included standard EEG with six derivations,
electrooculogram and electrocardiogram. Other measure-
ments included electromyogram (chin and tibial muscles),
nasal–oral flow, thoracic and abdominal respiratory ef-
forts, oxyhemoglobin saturation, sound and body position.
No transcutaneous PCO2 was measured. Sleep staging
was scored using the American Academy of Sleep
Medicine manual or Rechtschaffen & Kales for the
scoring of sleep and associated events [21, 22]. All
events were calculated per hour of sleep (index). In 11
of the PWS children, at least one PSG was performed
before or shortly after ITT or GT (mean time between
PSG and the stimulation test: - 0.37 ± 0.39 years). PSG
data were retrieved from the respective archives and
reviewed by the same pediatric neurologist (KD) spe-
cialized in sleep disorders, in order to calculate the CA
and OA index. An OA index equal to or less than 1 per
hour and a CA index of ≤ 0.9 per hour were considered
as normal [23].
Results were statistically analyzed with the Statistical
Package for Social Sciences (SPSS 20.0, Chicago, IL).
Results are presented as median (95 % confidence interval
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(CI95%)) calculated according to Hodges-Lehmann or as
mean ± SEM or as %. To test if the variance of the cortisol
levels was different between the two groups (PWS and
controls) and between the two stimulation tests (ITT and
GT), the O’Brien test for the homogeneity of the variance
was applied. Comparative analyses were done using the
Mann Whitney test and correlation analysis using non
parametric Kendall’s tau correlation. A p-value <0.05 was
considered significant.
The study was approved by our local medical ethical com-
mittee of UZ Ghent university hospital (B.U.N.143201112296).
Results
Clinical characteristics
At GH testing, PWS patients were slightly but not sig-
nificantly younger than the controls (respectively, median
(CI 95 %) age: 5.6 (3.8;8.3) vs. 8.2 (6.6;10.2) years; p = 0.12).
As expected, BMI-Z-score was higher in the PWS group
than in the control group (BMI z-score respectively, me-
dian (CI 95 %): 1.65 (0.5; 2.7) vs. -0.65 (-1.11; -0.15) kg/m2,
p = 0.0001). Nine (45 %) of the patients were boys in the
PWS group and 16 (48 %) in the control group.
GH status
In the PWS group (Table 1), six patients (30 %) had under-
gone an ITT, thirteen (65 %) a GT, in one child (# 14), both
ITT and GT had been performed. ITT and/or GT was
suggestive of GH deficiency in 50 % of the PWS children.
The median (CI 95 %) age at start of GH therapy was
5 (3.7; 6.6) years.
PSG results
Eleven of these children had undergone a PSG on average
0.37 ± 0.39 years before the GH stimulation test (Table 1).
Four of them exhibited an increased CA index in com-
parison to the others of the group.
Cortisol response
In one (# 8) out of twenty PWS patients, CAI was
suspected, based on an insufficient cortisol peak value of
16.6 μg/dl after ITT. The only child with CAI had a CA
index similar to the others of the PWS children, whereas
the four PWS children with a raised CA index reached a
sufficient cortisol response during the stimulation test
(Table 1).
Table 1 Summary of PWS patient characteristics and overview of their laboratory and PSG results
# Age (y) at
start of GH
GH
Status
Age (y) at
the test
ITT/GT Peak cortisol
(μg/dl)
Cortisol increase
(μg/dl)
Δ (y) age at PSG
and age at test
BMI z-score
at PSG
CA
index
OA
index
Tonsil-
lectomy
1 1,9 normal 1,7 GT 30,78 23,07 - - - - -
2 2 GHD 1,8 GT 41,98 32,17 −0,76 −0.5 0,7 0 1
3 3,8 normal 2,9 GT 26,5 9,0 - - - - -
4 5 normal 3,3 GT 20,6 12,6 - - - - -
5 3,4 GHD 3,4 GT 39,3 27,3 0,34 3.6 0,1 15 1
6 5,4 GHD 5,4 GT 31,4 18,7 1,71 2.9 0,1 13,4 1
7 12,1 normal 12 GT 20,2 15,84 - - - - -
8 8,5 GHD 14,4 ITT 16,6 9,97 −1,82 1.4 0,6 0,4 3
9 1 normal 0,8 GT 38,32 18,75 −0,22 −2.1 1,9 0,1 3
10 4,2 GHD 3,5 ITT 33,11 13,07 0,5 5.7 5,1 0 3
11 3,8 GHD 3,7 GT 47,1 19,9 0,05 −0.2 0,7 0,5 1
12 5 normal 4,4 ITT 23,45 16,4 - - - - -
13 5,2 normal 4,7 ITT 30,83 20,07 - - - - -
14 6,9 normal 5,5 GT 26.3 19.44 - - - - -
5,6 ITT 24.0 16.92 - - - - -
15 2,9 normal 5,9 GT 31,5 24,69 −3,08 −0.8 0 4,2 3
16 6,2 GHD 6 GT 26,34 18,28 0 0.9 2,8 0,3 3
17 5,5 GHD 7,7 ITT 26,82 22,9 0,27 3.9 0,6 0,2 2
18 NA GHD 9,4 GT 23,6 17,09 - - - - -
19 13,9 normal 12,2 ITT 29,3 12,5 - - - - -
20 5,4 GHD 14,7 GT 20,88 17,33 −1,02 3.1 1,2 0,5 3
y years, GH Growth Hormone, ITT insulin tolerance test, GT glucagon test; cortisol increase was calculated between the lowest cortisol and the highest cortisol
level during the stimulation test, PSG polysomnography, BMI body mass index, CA index central apnea index (#/hour), OA index obstructive apnea index (#/hour),
NA not applicable; tonsillectomy:1 = performed after PGS, 2 = before PGS, 3 = no tonsillectomy
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Basal cortisol levels did not differ between the PWS
and the control children (p = 0.20) (Fig. 1a). Peak
cortisol levels (Fig. 1b) and cortisol increase (Fig. 1c)
were also not significantly different between the two
groups (respectively p = 0.7 and p = 0.64). In both the
PWS and control group, no difference was observed
between the GT- or the ITT-induced peak cortisol
response (respectively, p = 0.57 and p = 0.73) or cortisol
increase (respectively, p = 0.24 and p = 0.63). Therefore
results of both tests were combined for the correlation
analysis. The variance of the cortisol levels was not
statistically different between the two groups (PWS
and controls) and between the two stimulation tests
(ITT and GT) (PWS versus control group: basal cortisol
levels, p = 0.55; peak cortisol levels, p = 0.505; cortisol
increase, p = 0.57; ITT versus GT, even after adjustment
for the group: basal cortisol levels, p = 0.44; peak corti-
sol levels, p = 0.49; cortisol increase, p = 0.16). No
significant correlation between peak cortisol levels or
cortisol increase was found with gender, BMI-z-score,
GH peak or GH status neither in the PWS group nor in
the control group (Table 2). However, the cortisol peak
value showed a significant inverse correlation with age
in both PWS and control children (Fig. 2) (respectively,
PWS Controls0
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Controls 
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Controls 
ITT
0
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40
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50
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ITT
0
5
10
15
20
25
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(C)
(B)
Fig. 1 a basal, b peak cortisol levels and c cortisol increase in PWS and control children after a glucagon (GT) or an insulin tolerance test (ITT).
The black lines represent the medians
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p = 0.012 and p = 0.0067). The decrease with age of the
peak cortisol levels after stimulation test was similar in the
two groups (p = 0.13). A similar inverse correlation
between cortisol increase during the stimulation test and
age was present but only significant in the control group.
A significant relationship between cortisol response and
CA index (Fig. 3), or other PSG parameters in PWS
children could not be demonstrated.
Discussion
Our data, based on peak cortisol and cortisol increase
after ITT or GT, showed an insufficient cortisol response
in only one out of twenty PWS children (5 %). We could
not replicate the hormonal findings by de Lind van
Wijngaarden et al. [10] who found CAI to be present in
60 % of PWS children, based on a metyrapone test. Our
results are in line with the results from Nyunt et al., Corrias
et al., Grugni et al. and Farholt et al. [12–15], who found
CAI in respectively 0, 4.8, 7.5 and 0 % of the PWS patients.
The optimal test for evaluating central adrenal insufficiency
in children is debated and the discrepancies in the
Table 2 Correlation of peak cortisol levels and cortisol increase
in PWS and control children
p= PWS Controls
Peak
cortisol
Cortisol
increase
Peak
cortisol
Cortisol
increase
Age 0.012* 0.64 0.0067* 0.058*
Sex 0.99 0.99 0.38 0.25
BMI-z-score 0.83 0.83 0.10 0.90
GH peak 0.53 0.88 0.40 0.56
GH status 0.43 0.43 NA NA
CA index 0.94 0.14 NA NA
OA index 0.75 0.64 NA NA
GH Growth hormone, GH status: normal or GH deficiency, CA central apnea,
OA obstructive apnea, NA not applicable
*p < 0.05
Fig. 2 Correlation between peak cortisol levels (upper panel) and cortisol increase (lower panel) and age at the stimulation test in PWS
(black square) and control (grey triangle) children
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prevalence of CAI between studies may be due to the dif-
ferent kind of tests used. The low prevalence of CAI re-
ported by Nyunt et al., Corrias et al. and Grugni et al. may
be due to the lack of sensitivity of the LDST they used to
diagnose CAI: only 50 % of the patients with an ACTH de-
ficiency, based on metyrapone tests showed an insufficient
cortisol response when tested with LDST [24, 25]. On the
other hand, as compared to ITT, the metyrapone test with
an ACTH cut-off of 33 pmol/l as it was used by de Lind
van Wijngaarden et al. [10] yielded a high false-positive rate
(specificity 47 %) [26]. In fact, ITT remains the gold stand-
ard test for evaluating central adrenal insufficiency in
children [19, 20]. Given its possible complications, the GT
is considered an equal and safe alternative and yielding
similar cortisol responses [18, 27, 28]. In our study, based
on these tests, we could not confirm the high prevalence of
CAI in PWS children.
We did not find any significant correlations between
cortisol response and PSG parameters and, in particular,
the CA index. Thus, our results do not support the
hypothesis of a link between CAI and SRBD, as sug-
gested by de Lind van Wijngaarden et al. [11]. Moreover,
in our study, the only child with CAI was 14.4 years old
when tested. As shown by others in PWS patients youn-
ger than 17 years of age [13, 14], the peak cortisol after
stimulation decreased in function of age. In our study,
this inverse correlation was also found in controls, and
thus is probably not related to the pathophysiology
underlying PWS. Sudden unexplained deaths in PWS
have been described to occur more frequently at a young
age [9]. We did not observe abnormal stress-induced
cortisol responses in young PWS patients. Therefore, a
causal link between sudden death and CAI as suggested
by de Lind van Wijngaarden et al. [10] seems to be
unlikely from our study.
Our study has methodological limitations due to its retro-
spective design and multicenter data collection. Although a
large variability in cortisol levels was found, the dispersion
of the cortisol levels was not different in PWS as compared
to controls or in the GT as compared to the ITT. The lack
of a standard cortisol assay method may explain some of
the variability in the cortisol levels reported in this study.
Indeed, Kaslaukaité et al. have shown in a meta-analysis
that, due to the lack of cortisol assay standardization,
Fig. 3 Correlation between peak cortisol levels (upper panel) and cortisol increase (lower panel) and central apnea (CA) index in PWS children
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the error in measuring cortisol can be up to 6 μg/dl
(165 nmol/l) between studies [19]. Moreover, a varia-
bility in peak cortisol response to insulin-induced
hypoglycemia is a common finding and an average vari-
ability of 8 to 12% has been reported by Vestergraard et al.
[29]. A suboptimal cortisol response to a glucagon stimu-
lation test [30] has also been reported in 8 % of healthy
individuals. The sample size was small, both due to the
rarity of the condition and to the lack of a standardized
protocol for the diagnosis and management of PWS
patients with regard to diagnosis of CAI and/or SRBD in
Belgium. However, by combining the data obtained after
ITT and GT, and by including a large control group, our
study reached sufficient power to reliably estimate the
prevalence of CAI in our patients and to investigate corre-
lations between cortisol response and PSG parameters.
Conclusion
CAI is a rare phenomenon in PWS. Our data do not sup-
port the theory of an overarching hypothalamic dysfunction
resulting in both hypothalamic-pituitary-adrenal axis and
central respiratory dysregulation. A causal link of CAI with
the reported sudden, unexplained deaths at a young age is
unlikely.
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